Home » Procurement Tender News » Tender Details
Procurement And Tender News

Tendersinfo keep you informed about the latest events in the national and international Procurement Industry. Procurement News provides in-depth coverage of the procurement industry, including contract awards, contract additions, new contract wins, mergers and acquisitions. Tendersinfo through its tender news section provides an update on all domestic and global tendering opportunities, invitation to bid & trade leads.

Luxembourg : Investment Plan for Europe: EIB backs German cancer therapy developer MagForce with up to EUR 35m
Publish Date : 11-Aug-2017

Patients who suffer from the most aggressive type of brain cancer, glioblastoma, will soon have broader access to a new form of treatment thanks to financing by the European Investment Bank (EIB). The EIB and German medical device company MagForce signed a financing agreement which will allow the company to borrow up to EUR 35 million over the coming three years, subject to achieving a set of agreed performance criteria.

The transaction with MagForce was made possible by the European Fund for Strategic Investments (EFSI). EFSI is the central pillar of the Investment Plan for Europe, in which the EIB Group and the European Commission as strategic partners aim to boost the competitiveness of the European economy.

MagForce has developed NanoTherm therapy, a new approach to the local treatment of solid tumours. The method is based on the principle of introducing magnetic nanoparticles directly into a tumour and then heating them in an alternating magnetic field. Depending on the duration of treatment and the temperatures achieved within the tumour, the tumour cells are either irreparably damaged or sensitised for additional chemo or radiotherapy.

This approach makes it possible to combat the tumour from within, while sparing surrounding healthy tissue. The side effects of the treatment are significantly lower than those in the standard methods currently used. In addition, the NanoTherm therapy displays a high degree of efficacy proven in clinical studies. It received regulatory approval for brain cancer in Europe, and patients are already successfully treated in Germany.

EIB financing will support NanoTherms Europe-wide roll-out for brain cancer therapy. Furthermore, the facility will support European and global approval for prostate cancer another oncological condition, which can be treated with NanoTherm therapy. In addition, MagForce is working on next generation nanoparticles, which will not only be able to generate heat but can also be used as drug transport mechanisms.

More than 20 million people worldwide are expected to live with cancer in the year 2030 a 50% increase from the levels of 2012, said Ambroise Fayolle, Vice-President of the EIB and responsible for operations in Germany. The therapy developed by MagForce has the potential to considerably ease the burden for some of those patients, and I am proud that EIB backing will actually help save peoples lives. The EU bank provides long-term and stable capital support to the companys R&D which will enable MagForce to accelerate the market launch of new treatments. Its this type of support for innovative companies that is crucial to strengthening Europes competitiveness.

Ben Lipps, Chief Executive Officer of MagForce, commented: We are honored that MagForce is backed by the European Fund for Strategic Investments. The loan will significantly enhance our financial standing and help us to roll-out MagForces NanoTherm therapy across Europe. It will also support the development and global commercialisation of prostate cancer solutions and MagForce's next generation NanoTherm.

European Commission Vice-President Jyrki Katainen, responsible for Jobs, Growth, Investment and Competitiveness, said: "The European Commission is committed to promoting investment in research and innovation. I am delighted that, with today's agreement, the Plan is contributing to the development of sophisticated new treatments for cancer patients. This is a very tangible example of the powerful impact EU support for investments can bring about."

Go to previous page